Pulmonary hypertension complicating multiple myeloma
- PMID: 26401262
- PMCID: PMC4556512
- DOI: 10.1086/682430
Pulmonary hypertension complicating multiple myeloma
Abstract
Pulmonary hypertension (PH) is an infrequently reported complication of multiple myeloma (MM). PH has been more commonly associated with amyloidosis, myeloproliferative diseases, and the POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome. PH in MM is typically mild to moderate and may be secondary to a variety of conditions, which include left ventricular dysfunction, high-output cardiac failure, chronic kidney disease, treatment-related toxicities, and precapillary involvement. We describe 3 patients with MM and severe PH. Each patient underwent right heart catheterization. All patients demonstrated elevated pulmonary pressures, transpulmonary gradients, and pulmonary vascular resistance. Each patient was ultimately treated with pulmonary vasodilator therapy with improvement in cardiopulmonary symptoms. Additional studies are needed to define the prevalence, prognosis, and pathogenesis of PH in this complex population and to help clarify who may benefit from targeted PH therapy.
Keywords: amyloidosis; multiple myeloma; pulmonary hypertension; pulmonary vasculature.
References
-
- Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–49. - PubMed
-
- Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52:347–361. - PubMed
-
- Smith TJ, Kyle RA, Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc 1984;59(8):547–555. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
